Literature DB >> 212153

The benzodiazepine receptor in normal and pathological human brain.

H Möhler, T Okada.   

Abstract

Benzodiazepines bind with high affinity to a specific benzodiazepine receptor, which occurs exclusively in the central nervous system. The affinity of various benzodiazepines to the receptor closely parallels their pharmacological and therapeutic potency. Binding to the receptor is stereospecific. The receptor is mainly localized in the synaptic membrane fraction and has its highest density in cortical areas of the brain. In Huntington's chorea a decrease in benzodiazepine receptor binding is found in caudate nucleus and putamen, which, at least in putamen, is due to a loss of benzodiazepine receptors apparently located on GABA neurones, which degenerate in Huntington's chorea. The loss of benzodiazepine receptors might explain why the ameliorative effects of benzodiazepines in the early stages of the disease are not sustained in the later stages.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 212153     DOI: 10.1192/bjp.133.3.261

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  20 in total

Review 1.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 2.  Relationships between CSF drug concentrations, receptor binding characteristics, and pharmacokinetic and pharmacodynamic properties of selected 1,4-substituted benzodiazepines.

Authors:  W A Colburn; M L Jack
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 3.  From binding studies to the molecular biology of GABA receptors.

Authors:  R J Knapp; E Malatynska; H I Yamamura
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

4.  Benzodiazepines: clinical pharmacology and therapeutic use.

Authors:  C Bellantuono; V Reggi; G Tognoni; S Garattini
Journal:  Drugs       Date:  1980-03       Impact factor: 9.546

Review 5.  Anxiogenic properties of beta-CCE and FG 7142: a review of promises and pitfalls.

Authors:  M H Thiébot; P Soubrié; D Sanger
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 6.  Alteration of GABAergic neurotransmission in Huntington's disease.

Authors:  Maurice Garret; Zhuowei Du; Marine Chazalon; Yoon H Cho; Jérôme Baufreton
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

7.  The effect of repeated doses of temazepam and nitrazepam on human psychomotor performance.

Authors:  G Tedeschi; A N Griffiths; A T Smith; A Richens
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

8.  Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship.

Authors:  J W Mandema; M T Kuck; M Danhof
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

9.  Depletion in amygdaloid 5-hydroxytryptamine concentration and changes in social and aggressive behaviour.

Authors:  S E File; T A James; N K MacLeod
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

10.  1-Methyl-beta-carboline (harmane), a potent endogenous inhibitor of benzodiazepine receptor binding.

Authors:  H Rommelspacher; C Nanz; H O Borbe; K J Fehske; W E Müller; U Wollert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.